Government-Owned Inventions; Availability for Licensing, 14141-14142 [2015-06123]
Download as PDF
<![CDATA[
14141
Federal Register / Vol. 80, No. 52 / Wednesday, March 18, 2015 / Notices
information collection. This is a onetime data collection effort.
CDC will use the information to
examine health systems and
dissemination of health systems
technology. Primary care practices will
use the results to inform their systems
for managing patients with chronic
conditions and to improve the quality of
care delivered. NCHS and CDC will also
use the results to improve technical
assistance to public health partners.
OMB approval is requested for two
years. Participation in the survey is
voluntary and all responses CDC will
de-identify all responses. There are no
costs to respondents other than their
time. The total estimated annualized
burden hours are 429.
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Type of respondent
Form name
Physician .........................................................
Physician .........................................................
Medical Secretary ...........................................
Physician .........................................................
Cognitive Testing Screener ............................
Cognitive Testing Protocol .............................
NSPCP Screener ...........................................
NSPCP ...........................................................
Leroy A. Richardson,
Chief, Information Collection Review Office,
Office of Scientific Integrity, Office of the
Associate Director for Science, Office of the
Director, Centers for Disease Control and
Prevention.
[FR Doc. 2015–06159 Filed 3–17–15; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Arthritis and
Musculoskeletal and Skin Diseases;
Notice of Closed Meeting
mstockstill on DSK4VPTVN1PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the Board
of Scientific Counselors, NIAMS.
The meeting will be closed to the
public as indicated below in accordance
with the provisions set forth in section
552b(c)(6), Title 5 U.S.C., as amended
for the review, discussion, and
evaluation of individual intramural
programs and projects conducted by the
National Institute of Arthritis and
Musculoskeletal and Skin Diseases,
including consideration of personnel
qualifications and performance, and the
competence of individual investigators,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Board of Scientific
Counselors, NIAMS.
Date: April 15–16, 2015.
Time: 6:00 p.m. to 3:45 p.m.
Agenda: To review and evaluate personal
qualifications and performance, and
competence of individual investigators.
Place: National Institutes of Health,
Building 31, Room 4C32, 31 Center Drive,
Bethesda, MD 20892.
Contact Person: John J. O’Shea, MD, Ph.D.,
Scientific Director, National Institute of
VerDate Sep<11>2014
19:00 Mar 17, 2015
Jkt 235001
Arthritis & Musculoskeletal and Skin
Diseases, Building 10, Room 9N228, MSC
1820, Bethesda, MD 20892, (301) 496–2612,
osheaj@arb.niams.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.846, Arthritis,
Musculoskeletal and Skin Diseases Research,
National Institutes of Health, HHS).
Dated: March 12, 2015.
Carolyn Baum,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2015–06122 Filed 3–17–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 209 and 37 CFR part 404 to
achieve expeditious commercialization
of results of federally-funded research
and development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Licensing information and copies of the
U.S. patent applications listed below
SUMMARY:
PO 00000
Frm 00072
Fmt 4703
Sfmt 4703
Number
responses per
respondent
25
15
1,500
473
1
1
1
1
Average
burden per
response
(in hours)
5/60
1.25
10/60
20/60
may be obtained by writing to the
indicated licensing contact at the Office
of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301–
496–7057; fax: 301–402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
SUPPLEMENTARY INFORMATION:
Technology descriptions follow.
GTF2I Mutations as Genetic Marker for
Prognosis of Thymic Malignancies
Description of Technology: The
present invention describes the
presence of a mutation in the general
transcription factor IIi (GTF2I) gene in
indolent thymic tumors that is rarely
found in more aggressive thymic
tumors.
The invention provides a method of
determining the prognosis of thymic
cancer in a patient by assaying (for
example using PCR based methods) the
genetic material obtained from the
patient tissue to detect a mutation in at
least one copy of GTF2I genetic
sequence; and correlating the presence
of a GTF2I mutation with the prognosis
of a thymic cancer patient, the presence
of the mutation indicating that the
thymic cancer is indolent.
A genetic test will complement the
diagnostic assessment, facilitate
development of a molecular
classification and assessment for the
clinical management of thymic cancers.
Potential Commercial Applications:
• A diagnostic test kit for the
prognosis and clinical management of
thymic cancer.
• Clinical decision whether treatment
is needed (for example, additional
treatment after surgery).
• Therapeutic decision making,
between an aggressive course of
E:\FR\FM\18MRN1.SGM
18MRN1
14142
Federal Register / Vol. 80, No. 52 / Wednesday, March 18, 2015 / Notices
treatment for more aggressive cancers
versus non aggressive treatment.
Competitive Advantages: The PCR
based method is more advantageous and
more objective than currently available
histological classification and staging
systems.
Development Stage:
• Early-stage.
• In vitro data available.
• In vivo data available (human).
Inventors: Guiseppe Giaccone and
Yisong Wang (NCI).
Publication: Petrini I, et al. A specific
missense mutation in GTF2I occurs at
high frequency in thymic epithelial
tumors. Nat Genet. 2014 Aug;46(8):844–
9. [PMID 24974848].
Intellectual Property: HHS Reference
No. E–109–2014/0—US Provisional
Application No. 61/975,222 filed April
4, 2014.
Licensing Contact: Sabarni Chatterjee,
Ph.D., MBA; 301–435–5587;
chatterjeesa@mail.nih.gov.
Collaborative Research Opportunity:
For collaboration opportunities, please
contact Dr. Guiseppe Giaccone at
gg496@georgetown.edu.
mstockstill on DSK4VPTVN1PROD with NOTICES
Systems and Devices for Training and
Imaging an Awake Test Animal
Description of Technology: The
invention pertains to an apparatus and
training system for rodents to maintain
its head substantially motionless during
an imaging procedure. The system
includes a frame defining an enclosure
for enclosing an animal therein during
the imaging procedure which has a head
post attached to the head of the animal
and a treadmill having a plurality of
rollers that the animal walks on such
that one or more of the plurality of
wheels rotate when the animal is in
walking motion and stop rotating when
the animal is in a substantially
motionless state. This arrangement
trains the animal to remain substantially
motionless when disposed within an
imaging apparatus. This invention
permits prolonged imaging of awake
rodents with minimal confinement and
reduces stress.
Potential Commercial Applications:
• Imaging test rodents.
• Imaging pharmacological agent
distribution in rodents.
• Imaging the therapeutically effects
of pharmacological agent.
Competitive Advantages: Imaging
while animal is awake.
Development Stage:
• Early-stage.
• Prototype.
Inventors: Hanbing Lu, Yihong Yang,
Elliot Stein (all of NIDA).
Intellectual Property: HHS Reference
No. E–043–2015/0—US Patent
VerDate Sep<11>2014
19:00 Mar 17, 2015
Jkt 235001
Application 14/589,725 filed January 5,
2015.
Licensing Contact: Michael
Shmilovich; 301–435–5019; shmilovm@
mail.nih.gov.
Collaborative Research Opportunity:
The National Institute on Drug Abuse is
seeking statements of capability or
interest from parties interested in
collaborative research to further develop
apparatus and/or the training system;
commercialize with pharmaceutical
industry. For collaboration
opportunities, please contact Vio
Conley, M.S. at conleyv@mail.nih.gov.
Miniature System for Manipulating
Small Animals in High-Throughput
Screening Small Molecules
Description of Technology: The
invention pertains to a miniaturized
plating and feeding system based on a
96-well microplate base and is intended
to reduce manipulation of organisms as
well as amounts of test drug/anesthetic,
thereby mitigating waste. The kit
comprises a feeder plate, transfer
adaptor and receiver plate. The feeder
plate is defined by, for example, a
plastic 96-well plate with rounded
wells. The rounded bottoms can
dispense to or permit access to the test
organism of liquid food or drug through
about 7 holes of approximately 350
microns in diameter. A top portion of
the well provides test organisms (e.g.,
drosophila, daphnia) with sufficient
space to enjoy normal life-cycles
without confinement stress. The feeder
plate includes means for interfacing
with complementary components of the
transfer and receiver plates through
receiving holes and complementary
dowels or pins. A transfer adapter
allows the interconnection of the feeder
plate to the receiver plate. The transfer
plate can be configured to be square or
rounded for the transfer of organisms
from the feeder plate to the receiver
plate.
Potential Commercial Applications:
• Drug Development.
• Toxicity Studies.
• Drug Design.
Competitive Advantages:
• Small animals.
• High Throughput.
• Space efficiency.
• Resource economy.
Development Stage:
• Early stage.
• Prototype.
Inventors: Maria De Los Angeles Jaime
and Brian Oliver (NIDDK).
Intellectual Property: HHS Reference
No. E–034–2015/0—US Provisional
Application No. 62/080,181 filed
November 14, 2014.
PO 00000
Frm 00073
Fmt 4703
Sfmt 4703
Licensing Contact: Michael
Shmilovich, Esq.; 301–435–5019;
shmilovm@mail.nih.gov.
Collaborative Research Opportunity:
The National Institute of Diabetes and
Digestive and Kidney Diseases is
seeking statements of capability or
interest from parties interested in
collaborative research to further
develop, evaluate or commercialize
High-Throughput Small Animal
Manipulation for Drug Design. For
collaboration opportunities, please
contact Marguerite J. Miller at
millermarg@niddk.nih.gov.
This abstract replaces one published
on Thursday, January 29, 2015 (80 FR
4935) to correct the patent application
filing date.
Dated: March 12, 2015.
Richard U. Rodriguez, M.B.A.,
Acting Director, Office of Technology
Transfer, National Institutes of Health.
[FR Doc. 2015–06123 Filed 3–17–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR Panel:
Cancer Health Disparities/Diversity in Basic
Cancer Research.
Date: April 13–14, 2015.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Embassy Suites at the Chevy Chase
Pavilion, 4300 Military Road, NW.,
Washington, DC 20015.
Contact Person: Nywana Sizemore, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6204,
MSC 7804, Bethesda, MD 20892, 301–435–
1718, sizemoren@csr.nih.gov.
E:\FR\FM\18MRN1.SGM
18MRN1
]]>Agencies
[Federal Register Volume 80, Number 52 (Wednesday, March 18, 2015)]
[Notices]
[Pages 14141-14142]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2015-06123]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Licensing information and copies of
the U.S. patent applications listed below may be obtained by writing to
the indicated licensing contact at the Office of Technology Transfer,
National Institutes of Health, 6011 Executive Boulevard, Suite 325,
Rockville, Maryland 20852-3804; telephone: 301-496-7057; fax: 301-402-
0220. A signed Confidential Disclosure Agreement will be required to
receive copies of the patent applications.
SUPPLEMENTARY INFORMATION: Technology descriptions follow.
GTF2I Mutations as Genetic Marker for Prognosis of Thymic Malignancies
Description of Technology: The present invention describes the
presence of a mutation in the general transcription factor IIi (GTF2I)
gene in indolent thymic tumors that is rarely found in more aggressive
thymic tumors.
The invention provides a method of determining the prognosis of
thymic cancer in a patient by assaying (for example using PCR based
methods) the genetic material obtained from the patient tissue to
detect a mutation in at least one copy of GTF2I genetic sequence; and
correlating the presence of a GTF2I mutation with the prognosis of a
thymic cancer patient, the presence of the mutation indicating that the
thymic cancer is indolent.
A genetic test will complement the diagnostic assessment,
facilitate development of a molecular classification and assessment for
the clinical management of thymic cancers.
Potential Commercial Applications:
A diagnostic test kit for the prognosis and clinical
management of thymic cancer.
Clinical decision whether treatment is needed (for
example, additional treatment after surgery).
Therapeutic decision making, between an aggressive course
of
[[Page 14142]]
treatment for more aggressive cancers versus non aggressive treatment.
Competitive Advantages: The PCR based method is more advantageous
and more objective than currently available histological classification
and staging systems.
Development Stage:
Early-stage.
In vitro data available.
In vivo data available (human).
Inventors: Guiseppe Giaccone and Yisong Wang (NCI).
Publication: Petrini I, et al. A specific missense mutation in
GTF2I occurs at high frequency in thymic epithelial tumors. Nat Genet.
2014 Aug;46(8):844-9. [PMID 24974848].
Intellectual Property: HHS Reference No. E-109-2014/0--US
Provisional Application No. 61/975,222 filed April 4, 2014.
Licensing Contact: Sabarni Chatterjee, Ph.D., MBA; 301-435-5587;
chatterjeesa@mail.nih.gov.
Collaborative Research Opportunity: For collaboration
opportunities, please contact Dr. Guiseppe Giaccone at
gg496@georgetown.edu.
Systems and Devices for Training and Imaging an Awake Test Animal
Description of Technology: The invention pertains to an apparatus
and training system for rodents to maintain its head substantially
motionless during an imaging procedure. The system includes a frame
defining an enclosure for enclosing an animal therein during the
imaging procedure which has a head post attached to the head of the
animal and a treadmill having a plurality of rollers that the animal
walks on such that one or more of the plurality of wheels rotate when
the animal is in walking motion and stop rotating when the animal is in
a substantially motionless state. This arrangement trains the animal to
remain substantially motionless when disposed within an imaging
apparatus. This invention permits prolonged imaging of awake rodents
with minimal confinement and reduces stress.
Potential Commercial Applications:
Imaging test rodents.
Imaging pharmacological agent distribution in rodents.
Imaging the therapeutically effects of pharmacological
agent.
Competitive Advantages: Imaging while animal is awake.
Development Stage:
Early-stage.
Prototype.
Inventors: Hanbing Lu, Yihong Yang, Elliot Stein (all of NIDA).
Intellectual Property: HHS Reference No. E-043-2015/0--US Patent
Application 14/589,725 filed January 5, 2015.
Licensing Contact: Michael Shmilovich; 301-435-5019;
shmilovm@mail.nih.gov.
Collaborative Research Opportunity: The National Institute on Drug
Abuse is seeking statements of capability or interest from parties
interested in collaborative research to further develop apparatus and/
or the training system; commercialize with pharmaceutical industry. For
collaboration opportunities, please contact Vio Conley, M.S. at
conleyv@mail.nih.gov.
Miniature System for Manipulating Small Animals in High-Throughput
Screening Small Molecules
Description of Technology: The invention pertains to a miniaturized
plating and feeding system based on a 96-well microplate base and is
intended to reduce manipulation of organisms as well as amounts of test
drug/anesthetic, thereby mitigating waste. The kit comprises a feeder
plate, transfer adaptor and receiver plate. The feeder plate is defined
by, for example, a plastic 96-well plate with rounded wells. The
rounded bottoms can dispense to or permit access to the test organism
of liquid food or drug through about 7 holes of approximately 350
microns in diameter. A top portion of the well provides test organisms
(e.g., drosophila, daphnia) with sufficient space to enjoy normal life-
cycles without confinement stress. The feeder plate includes means for
interfacing with complementary components of the transfer and receiver
plates through receiving holes and complementary dowels or pins. A
transfer adapter allows the interconnection of the feeder plate to the
receiver plate. The transfer plate can be configured to be square or
rounded for the transfer of organisms from the feeder plate to the
receiver plate.
Potential Commercial Applications:
Drug Development.
Toxicity Studies.
Drug Design.
Competitive Advantages:
Small animals.
High Throughput.
Space efficiency.
Resource economy.
Development Stage:
Early stage.
Prototype.
Inventors: Maria De Los Angeles Jaime and Brian Oliver (NIDDK).
Intellectual Property: HHS Reference No. E-034-2015/0--US
Provisional Application No. 62/080,181 filed November 14, 2014.
Licensing Contact: Michael Shmilovich, Esq.; 301-435-5019;
shmilovm@mail.nih.gov.
Collaborative Research Opportunity: The National Institute of
Diabetes and Digestive and Kidney Diseases is seeking statements of
capability or interest from parties interested in collaborative
research to further develop, evaluate or commercialize High-Throughput
Small Animal Manipulation for Drug Design. For collaboration
opportunities, please contact Marguerite J. Miller at
millermarg@niddk.nih.gov.
This abstract replaces one published on Thursday, January 29, 2015
(80 FR 4935) to correct the patent application filing date.
Dated: March 12, 2015.
Richard U. Rodriguez, M.B.A.,
Acting Director, Office of Technology Transfer, National Institutes of
Health.
[FR Doc. 2015-06123 Filed 3-17-15; 8:45 am]
BILLING CODE 4140-01-P
